Share on StockTwits
 

DexCom (NASDAQ:DXCM) EVP Steven Robert Pacelli sold 14,000 shares of DexCom stock in a transaction that occurred on Thursday, January 23rd. The shares were sold at an average price of $36.49, for a total value of $510,860.00. Following the sale, the executive vice president now directly owns 195,865 shares in the company, valued at approximately $7,147,114. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

A number of analysts have recently weighed in on DXCM shares. Analysts at Canaccord Genuity reiterated a “buy” rating on shares of DexCom in a research note to investors on Friday. They now have a $44.00 price target on the stock. Separately, analysts at Benchmark Co. raised their price target on shares of DexCom from $40.00 to $44.00 in a research note to investors on Tuesday, January 14th. They now have a “buy” rating on the stock. Finally, analysts at Raymond James reiterated a “buy” rating on shares of DexCom in a research note to investors on Thursday, November 7th. They now have a $34.00 price target on the stock. Six research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $32.10.

Shares of DexCom (NASDAQ:DXCM) traded down 1.44% during mid-day trading on Monday, hitting $36.15. The stock had a trading volume of 959,496 shares. DexCom has a 1-year low of $14.05 and a 1-year high of $38.20. The stock has a 50-day moving average of $35.43 and a 200-day moving average of $29.82. The company’s market cap is $2.595 billion.

DexCom (NASDAQ:DXCM) last announced its earnings results on Wednesday, November 6th. The company reported ($0.09) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.13) by $0.04. The company had revenue of $42.90 million for the quarter, compared to the consensus estimate of $35.90 million. During the same quarter in the previous year, the company posted ($0.25) earnings per share. The company’s revenue for the quarter was up 85.7% on a year-over-year basis. Analysts expect that DexCom will post $-0.46 EPS for the current fiscal year.

DexCom, Inc (NASDAQ:DXCM) is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.